Dycom Industries Inc
Behind the Fidelity Blue Chip Growth Fund’s Disappointing Performance in 2016
FBGRX has had a below-average 2016 so far, placing seventh in our select peer group of 12 funds in terms of point-to-point returns.
What’s Been Ailing the Fidelity Blue Chip Growth Fund?
Stock picks from the healthcare sector are primarily responsible for FBGRX’s poor showing YTD. Allergan has hurt the sector, with Regeneron and Celgene.